Learn how testosterone production is regulated, why repeat testing matters and how external testosterone affects hormonal signaling and fertility.
Testosterone is a hormone produced by Leydig cells in the testes in response to hormonal instructions from the brain and pituitary gland. Its production depends on communication between these organs, rather than on the testes working independently.
The hypothalamus and pituitary are parts of the signaling system that directs the testes. The pituitary signal called luteinizing hormone, or LH, stimulates Leydig cells to produce testosterone. A review of male reproductive health describes this relationship alongside the signals involved in sperm production.
The basic sequence is:
Follicle-stimulating hormone, or FSH, has a related but different role. It supports Sertoli-cell function and sperm production. LH and FSH are the pituitary hormones called gonadotropins.
This distinction matters because making testosterone and supporting sperm production are connected processes without being interchangeable. A blood testosterone result is therefore only part of the picture when clinicians assess testicular signaling or fertility.
The system also helps explain why investigating a low result may involve more than measuring testosterone again. Clinicians may need to assess both the hormone being produced and the signals that normally stimulate its production.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret symptoms and laboratory results and discuss any treatment or fertility decisions.
There is an important distinction between a reference range and a threshold used during diagnosis. The European Association of Urology (EAU) guideline recommends confirming total testosterone below 12 nmol/L with repeat testing on at least two occasions.
The 12 nmol/L figure is a clinical decision point in that guidance. It is not a stand-alone diagnosis or an instruction to raise testosterone to a particular target. The EAU combines laboratory findings with compatible signs and symptoms when assessing late-onset hypogonadism.
Biologically, a blood testosterone measurement describes the hormone present in circulation. It does not identify whether a low result reflects impaired testicular function or inadequate stimulation from the hypothalamus and pituitary. That distinction requires a broader evaluation.
The reference-range question is therefore not simply whether a result falls above or below a line. A more useful discussion asks whether the result is reproducible and how it fits the rest of the hormonal system.
The EAU recommends sampling between 07:00 and 10:00 in fasting conditions and using a reliable assay. A low initial result needs confirmation rather than immediate interpretation as a settled diagnosis.
These conditions matter because the guideline notes that non-fasting testing may underestimate total testosterone by more than 30%. It also advises against measuring testosterone during acute illness. An unexpected result therefore needs to be considered alongside how and when the sample was collected.
This makes the circumstances of testing part of the interpretation. A clinician can assess whether the initial sample followed the recommended conditions and whether confirmation is needed before drawing conclusions.
The EAU distinguishes these broad patterns:
Measuring LH and FSH helps clinicians distinguish different forms of hypogonadism. Their role is to add information about signaling, not to replace the clinical history or identify every cause on their own.
A testosterone result answers a different question from an LH or FSH result. Considering them together helps connect the measured hormone level with the system responsible for producing it.
Symptoms are part of the assessment, but they are not a direct measurement of testosterone production. The EAU notes that symptoms associated with hypogonadism are not exclusive to that condition. Another health problem may therefore need consideration even when a complaint seems hormonal.
An adult man may have symptoms that prompt testing without meeting the diagnostic criteria for hypogonadism. Conversely, a low laboratory result without a compatible clinical picture does not fulfill the EAU's diagnostic approach. The assessment brings symptoms and confirmed biochemical findings together.
This is why considering other explanations for possible low-testosterone symptoms matters. The clinical question is not just whether testosterone is low. It is whether the symptoms and test results form a consistent picture after relevant health conditions and exposures are considered.
A result outside the expected interval also should not be used alone to infer how actively the testes are working. As the distinction between natural production and external testosterone shows, the source of hormone exposure matters too.
The EAU recommends checking for diseases, medicines and substances that can interfere with testosterone production or action. It also identifies obesity and other health conditions as important contributors to functional hypogonadism.
Relevant inputs include:
For overweight or obese men, the EAU recommends lifestyle and weight management before testosterone therapy. It characterizes the testosterone improvement associated with low-calorie diet and physical activity as small, about 1-2 nmol/L in the evidence it summarizes.
That finding describes evidence from particular clinical settings. It does not establish that one food or behavior will reliably produce a predictable hormone increase in every man. Lifestyle associations should not be turned into a personal testosterone formula.
The practical distinction is between addressing relevant health factors and promising a specific laboratory outcome. Weight management can belong in a clinician-led care discussion without being presented as a substitute for evaluating persistent symptoms or an unexplained low result.
For more context, Testostra's explanation of how weight management relates to testosterone considers why individual outcomes differ. The useful question is how weight and other health conditions fit a particular evaluation, not whether a single change will switch production on.
External testosterone is another major influence on this system. The EAU states that testosterone therapy suppresses gonadotropins, the body's own testosterone secretion and sperm production. Supplying testosterone therefore differs from preserving the body's usual signal-and-response process.
Blood testosterone can be treated while the hormonal drive to the testes is suppressed. A blood result alone consequently does not establish that natural testicular production or sperm production is being maintained.
This is an important distinction when discussing how testosterone therapy affects natural hormone production. The presence of testosterone in circulation and the strength of the signals stimulating the testes are related but separate clinical considerations.
Fertility goals need particular attention before treatment decisions. The EAU advises against testosterone therapy in men wishing to become fathers and against using it to treat male infertility. Raising blood testosterone should not be equated with improving sperm production.
These recommendations make fertility plans part of the treatment conversation rather than an unrelated issue. A qualified clinician can address those goals alongside the reason treatment is being considered and its effects on hormonal signaling.
“Do my symptoms and repeat morning testosterone results fit hypogonadism? Would LH and FSH help identify the cause? Could health conditions or medicines affect my results? How would treatment affect my own testosterone production and fertility?”
The next stage after understanding testosterone production is deciding which symptom questions belong in a clinical conversation, a step Testostra supports through clear hormone education. For men uncertain about changing symptoms, its articles explain possible hormonal causes alongside the role of testing while leaving diagnosis and treatment with qualified clinicians.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra